Enzo Biochem Inc. (ENZ) Announces Quarterly Earnings Results
Enzo Biochem Inc. (NYSE:ENZ) posted its earnings results on Thursday. The company reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.83. Enzo Biochem had a net margin of 17.27% and a negative return on equity of 20.77%. The business had revenue of $26.60 million for the quarter, compared to analysts’ expectations of $26 million. During the same period in the prior year, the company posted ($0.06) EPS.
Enzo Biochem (NYSE:ENZ) traded down 0.39% during trading on Thursday, hitting $5.07. 112,426 shares of the company traded hands. The company’s 50 day moving average is $5.36 and its 200-day moving average is $5.69. Enzo Biochem has a 52 week low of $3.48 and a 52 week high of $7.00. The stock has a market capitalization of $234.56 million, a PE ratio of 13.27 and a beta of 1.50.
A number of institutional investors have recently modified their holdings of the stock. Spark Investment Management LLC increased its position in shares of Enzo Biochem by 113.3% in the second quarter. Spark Investment Management LLC now owns 99,200 shares of the company’s stock valued at $592,000 after buying an additional 52,700 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Enzo Biochem during the second quarter valued at $233,000. Perceptive Advisors LLC purchased a new position in shares of Enzo Biochem during the second quarter valued at $401,000. Teachers Advisors Inc. purchased a new position in shares of Enzo Biochem during the second quarter valued at $373,000. Finally, American International Group Inc. increased its position in shares of Enzo Biochem by 2,184.6% in the second quarter. American International Group Inc. now owns 22,846 shares of the company’s stock valued at $136,000 after buying an additional 21,846 shares in the last quarter. 53.29% of the stock is currently owned by institutional investors and hedge funds.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/enzo-biochem-inc-enz-announces-quarterly-earnings-results-2.html
Separately, Zacks Investment Research upgraded shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research note on Thursday, June 16th.
About Enzo Biochem
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.